S&P US 500

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Antipa Minerals Limited

AZY

Antipa Minerals Ltd. engages in the exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-04-20. Its tenement holding covers over 4,100 square kilometers (km2) situated within an underexplored gold-copper-silver-cobalt province. The company has three growth projects, such as the Wilki Project, Paterson Project and Citadel JV Project. The Wilki Project comprises approximately 1,430km2 in total landholding and is located on the southern portion of its tenement ground in the Paterson Province of Western Australia. The 1,520 km2 Paterson Project is situated within 22 kilometers (km) of Greatland’s Telfer gold-copper silver mine and 22Mtpa mineral processing facility, 8km from Rio Tinto-Sumitomo’s Winu copper gold-silver development project. The Citadel JV Project adjoins its Paterson Project and includes the Magnum Dome, an area of approximately 30km2.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

NASDAQ US 100

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).